• Relay Therapeutics recently reported updated Phase 1/2 ReDiscover trial data showing that zovegalisib (RLY-2608) plus fulvestrant at a 400mg twice-daily fed dose delivered efficacy and tolerability in PI3Ka-mutated, HR+/HER2- metastatic breast cancer consistent with its earlier 600mg fasted regimen, and confirmed this as the recommended Phase 3 dose.
• The data, presented at ESMO TAT 2026, underpin the ongoing global Phase 3 ReDiscover-2 trial and build on the regimen’s FDA Breakthrough Therapy designation, reinforcing the clinical rationale for directly comparing zovegalisib plus fulvestrant against capivasertib plus fulvestrant.
• We’ll now look at what this Phase 1/2 confirmation of the Phase 3 dose means for Relay Therapeutics’ broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Relay Therapeutics' Investment Narrative?

To own Relay Therapeutics, you have to believe its structure‑based drug discovery engine can turn today’s heavy losses and modest US$15,355,000 in revenue into a sustainable oncology franchise, with zovegalisib at the center. The new ReDiscover Phase 1/2 data matter here: confirming the 400mg fed dose with efficacy and tolerability in line with the earlier 600mg fasted regimen helps de‑risk the ongoing ReDiscover‑2 Phase 3 trial, which is arguably the key short term catalyst after the stock’s very large 1‑year total return. The update does not change the fundamental risk profile of a single late‑stage asset in an unprofitable company, but it does sharpen the focus on execution, comparator risk versus capivasertib, cash burn and the importance of the RLY‑4008 partnership economics.

However, investors should be aware of how dependent Relay remains on zovegalisib’s late‑stage outcome. Our valuation report here indicates Relay Therapeutics may be overvalued.

Exploring Other Perspectives

The Simply Wall St Community currently has 1 fair value estimate clustered at US$16.64 per share, showing how even a single view can differ from market pricing. Set that against Relay’s reliance on zovegalisib’s Phase 3 outcome and ongoing losses, and it is clear you should weigh multiple perspectives before deciding how this story might fit into your portfolio.

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth just $16.64!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

No Opportunity In Relay Therapeutics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 54 companies with promising cash flow potential yet trading below their fair value.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.